北京万泰生物药业股份有限公司 第六届董事会第十四次会议决议公告

Core Viewpoint - The company has approved the use of idle funds for cash management, allowing for investments in low-risk financial products to enhance capital efficiency and shareholder returns [2][4][21]. Group 1: Board Meeting Overview - The sixth board meeting was held on January 13, 2026, with all nine directors present, confirming the legality and validity of the meeting [1][3]. - The board approved several resolutions, including the use of idle funds for cash management and the establishment of internal management systems [7][9]. Group 2: Use of Idle Funds - The company will use up to RMB 45 billion of idle self-owned funds for cash management, focusing on high-security, liquid low-risk investment products, valid for 12 months [2][14]. - The company will also use up to RMB 12 billion of temporarily idle raised funds for similar investments, ensuring that it does not affect ongoing projects [4][22]. Group 3: Investment Management - The investment strategy includes purchasing low-risk financial products with a maximum term of 12 months, ensuring liquidity and safety [14][26]. - The company will implement strict controls over the selection of investment products and will authorize the general manager to oversee the execution of these investments [15][28]. Group 4: Risk Management - The company acknowledges potential market risks due to macroeconomic factors but emphasizes that the investments are in low-risk categories [16][33]. - Risk control measures include regular monitoring of investment products and the establishment of a management system to ensure compliance with regulations [19][34]. Group 5: Impact on Company - The cash management strategy is designed to improve fund utilization efficiency without adversely affecting the company's operations or financial health [20][37]. - The company aims to maximize shareholder returns through prudent management of idle funds while ensuring compliance with relevant regulations [30][36].